Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

ITCI Stock - Intra Cellular Therapies Stock Trading


home / stock / itci

ITCI ITCI Quote ITCI Short ITCI News ITCI Articles ITCI Message Board

MWN AI Summary *

Intra-Cellular Therapies Inc. (NASDAQ: ITCI) is a biopharmaceutical company committed to advancing innovative therapies for neuropsychiatric diseases. The company's primary focus is on developing treatments for conditions such as schizophrenia, bipolar disorder, and depression. ITCI’s lead product, Caplyta (lumateperone), was approved by the U.S. Food and Drug Administration (FDA) in December 2019 for the treatment of schizophrenia in adults. Caplyta represents a new class of medications, offering an alternative to traditional antipsychotics with a potentially improved side effect profile.

ITCI is not only focused on schizophrenia; it is also exploring Caplyta’s potential in treating bipolar depression and major depressive disorder, alongside ongoing clinical trials aimed at expanding its indications. The versatility of lumateperone in addressing various neuropsychiatric conditions distinguishes ITCI within the biotech landscape.

Intra-Cellular Therapies has continued to build its market presence through strategic partnerships and collaborations. The company's research and development pipeline includes several promising drug candidates that leverage its proprietary technology platform. This platform aims to enhance the understanding of intracellular signaling pathways relevant to psychiatric disorders, which can lead to the discovery of novel therapeutics.

As of late 2023, ITCI has shown strong financial performance, bolstered by increasing sales of Caplyta and ongoing clinical advancements. The healthcare sector, particularly mental health, is gaining importance, and ITCI is well-positioned to capitalize on this trend. With a dedicated management team and a strong focus on innovation, Intra-Cellular Therapies Inc. is a significant player in the biopharmaceutical arena, committed to improving the lives of patients with challenging neuropsychiatric conditions. Investors continue to watch the company closely for developments in its clinical programs and overall market growth.

MWN AI Analysis *

Intra-Cellular Therapies Inc. (NASDAQ: ITCI) is an emerging biotech company focusing on the development of innovative therapies for neuropsychiatric diseases. As of October 2023, the company's flagship product, Caplyta (lumateperone), has shown promising results in the treatment of schizophrenia and recently gained traction in the treatment of bipolar depression. This positions ITCI favorably within a lucrative market, with the global psychiatric drugs market projected to expand significantly over the next several years.

From a financial perspective, ITCI has displayed impressive revenue growth since the commercial launch of Caplyta, achieving a notable increase in prescriptions. This surge reflects favorable physician adoption rates and an expanding patient base. Analysts have consistently upgraded their revenue estimates, suggesting a bullish sentiment surrounding the company’s financial trajectory.

However, potential investors should consider certain risks. The biotech sector is often volatile, and ITCI is no exception. The company remains heavily reliant on the success of Caplyta, with any setbacks in clinical trials for additional indications or adverse market dynamics posing risks to profitability. Additionally, competition within the neuropsychiatric drug landscape is intensifying, and ITCI must continue to innovate to maintain its market position.

From a valuation standpoint, ITCI's current price-to-sales ratio appears high compared to industry peers. While this could be justified by the company's growth prospects, investors might want to adopt a cautious approach, particularly if market conditions deteriorate or if Caplyta’s adoption slows.

In conclusion, while Intra-Cellular Therapies presents a compelling investment opportunity due to its growth potential and market position, potential investors should maintain diligent monitoring of the company’s pipeline developments, market competition, and broader economic indicators to make well-informed decisions.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Intra-Cellular Therapies Inc. (NASDAQ:ITCI)

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Quote | Intra-Cellular Therapies Inc. (NASDAQ:ITCI)

Last:$131.87
Change Percent: -0.02%
Open:$131.9
Close:$131.87
High:$131.98
Low:$131.63
Volume:16,062,974
Last Trade Date Time:04/01/2025 03:00:00 am

News | Intra-Cellular Therapies Inc. (NASDAQ:ITCI)

  • How the (ITCI) price action is used to our Advantage

    2025-06-02 20:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

    • June 02, 2025 08:34:00 pm

    • |
    • Stock Traders Daily
    • |
      • ITCI Stock
      • ITCI Quote
      • ITCI Short
      • ITCI News
      • ITCI Articles
      • ITCI Message Board
  • Franklin Biotechnology Discovery Fund Q4 2024 Commentary

    2025-03-27 07:30:00 ET Summary During Q4 2024, global stocks were pressured by investor concerns about economic growth, persistent inflation in some regions and the likelihood of further interest rate cuts in 2025. The fund had negative absolute and relative returns in the biotech...

    • March 27, 2025 07:30:00 am

    • |
    • SeekingAlpha
    • |
      • ITCI Stock
      • ITCI Quote
      • ITCI Short
      • ITCI News
      • ITCI Articles
      • ITCI Message Board

Message Board Posts | Intra-Cellular Therapies Inc. (NASDAQ:ITCI)

Subject By Source When
Geez..... No posting on this stock for over Chrisny73 investorshub 12/22/2021 9:28:10 PM
$ITCI > diluting > shelf placement last Friday! crudeoil24 investorshub 09/14/2020 5:32:46 PM
$ITCI respecting the ma20 on the 240min chart ~ $treet $inatra investorshub 09/14/2020 5:27:21 PM
znewcar1: ITCI 72% v43,9M c31.86 f67,3M gap up preMH42.99 S28.5 znewcar1 investorshangout 09/09/2020 9:09:29 PM
* * $ITCI Video Chart 09-09-2020 * * ClayTrader investorshub 09/09/2020 8:37:57 PM

MWN AI FAQ **

What recent developments or clinical trials have been reported by Intra-Cellular Therapies Inc. (NASDAQ: ITCI) that could impact their stock performance in the upcoming quarters?

Intra-Cellular Therapies Inc. has recently reported positive phase 3 trial results for its lead drug, lumateperone, in treating schizophrenia and depressive episodes associated with bipolar disorder, which may bolster investor confidence and positively influence stock performance.

How does Intra-Cellular Therapies Inc. ITCI plan to compete with other companies in the mental health treatment market moving forward?

Intra-Cellular Therapies Inc. (ITCI) plans to compete in the mental health treatment market by advancing its innovative therapies, focusing on research and development, forging strategic partnerships, and enhancing patient access to its treatments for conditions like schizophrenia and bipolar disorder.

What are analyst projections for revenue growth for Intra-Cellular Therapies Inc. (NASDAQ: ITCI) over the next 5 years, and what factors are driving these expectations?

Analysts project robust revenue growth for Intra-Cellular Therapies (NASDAQ: ITCI) over the next five years, driven primarily by the increasing adoption of its treatment for schizophrenia and potential new product launches in the pipeline.

How has Intra-Cellular Therapies Inc. ITCI's financial health and cash reserves changed in the last fiscal year, and how might this influence their R&D investments?

Intra-Cellular Therapies Inc. (ITCI) improved its financial health and cash reserves over the last fiscal year, which may bolster its ability to fund ongoing and future R&D investments, potentially accelerating the development of new therapeutics and enhancing its market position.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get ITCI Alerts

News, Short Squeeze, Breakout and More Instantly...

Intra-Cellular Therapies Inc. Company Name:

ITCI Stock Symbol:

NASDAQ Market:

-0.02% G/L:

$131.87 Last:

16,062,974 Volume:

$131.90 Open:

$131.87 Close:

Intra-Cellular Therapies Inc. Website:

Intra-Cellular Therapies Inc. Logo

Ad

Investor Relations
RECENT ITCI NEWS
  • ITCI - How the (ITCI) price action is used to our Advantage

    2025-06-02 20:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

  • ITCI - Kuehn Law Encourages Investors of Intra-Cellular Therapies, Inc. to Contact Law Firm

    New York, New York--(Newsfile Corp. - February 26, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) breached their duties to shareholders. The investigation concerns the propo...

  • ITCI - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITCI, PWOD, EBTC on Behalf of Shareholders

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITCI, PWOD, EBTC on Behalf of Shareholders PR Newswire NEW YORK , Feb. 26, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violatio...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get ITCI Alerts

Get ITCI Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1